pocket within the viral protein VP1 (3-barrel structure, although the orientation and position of each compound within the pocket was found to differ. The compounds cause the protein shell to be less flexible, thereby inhibiting disassembly. Although the antiviral potency of these compounds varies by 120-fold, they all induce the same conformational changes on the virion. The interactions of these compounds with the viral capsid are consistent with their observed antiviral activities against human rhinovirus 14 drug-resistant mutants and other rhinovirus serotypes. Crystallographic studies of one of these mutants confirm the partial sequencing data and support the finding that this is a single mutation that occurs within the binding pocket.
Picornaviruses are small RNA-containing animal viruses with molecular masses of approximately 8 .5 x 106 daltons (of which about 30% is due to RNA) and with external diameters of about 300 A. This family of viruses is responsible for diseases including the common cold, hepatitis A, poliomyelitis, and foot-and-mouth disease. Structures for the human rhinovirus (1), poliovirus (2) and Mengo virus (3) have been determined by x-ray crystallographic analysis to about 3 A resolution. The protein capsid of these viruses is composed of 60 protomers in an icosahedrally symmetric arrangement. Each protomer is composed of three surface viral proteins (VP1, VP2, and VP3) and a smaller internal protein (VP4). The three larger proteins are folded into eight-stranded antiparallel P-barrel structures and form a pseudo T = 3 (T = triangulation number) surface lattice. Surrounding each of the 12 pentamer axes on the rhinovirus surface is a 25 A deep canyon with four neutralizing immunogen sites on either rim of the canyon. The neutralizing immunogen sites are hypervariable between different rhinovirus serotypes, while the canyon floor is relatively well conserved. It has been proposed that the canyon is the site of the receptor attachment for the virus (1) .
A series of structurally related antiviral compounds ( Fig. 1 (4) has been found to inhibit picornaviral replication by preventing uncoating (5), as have some other structurally unrelated compounds (6, 7) . We have examined the binding of some of these compounds to human rhinovirus 14 (HRV14) in an extension of the work reported by Smith et al. (8) . All of these compounds bind into a hydrophobic pocket beneath the canyon floor (Fig. 2) accompanied by large (up to 5.5 A) conformational changes in the HRV14 structure from the native conformation in the vicinity of the binding site. Here we report and contrast the structures of the virus-drug complexes for eight analogues (Fig. 1) . We also report the structure ofa drug-resistant mutant. An attempt is made to rationalize biological activity measured in terms of MIC and the properties of the drug-resistant mutants.
Data Collection, Reduction, and Calculation of Electron Density Maps Cubic HRV14 crystals of diameter 0.25-0.45 mm (9) were soaked in solutions of the WIN compounds dissolved in dimethyl sulfoxide. The x-ray diffraction data were collected primarily at the Cornell High Energy Synchrotron Source (CHESS) and also (compound III) at the Brookhaven Laboratory's National Light Source. The resulting films were processed and scaled as described (10, 11) . Processing statistics appear in Table 1 .
Phase angles for the measured structure factor amplitudes of each virus-drug complex were obtained by the molecularreplacement real-space-averaging procedure (1, 12 Table 1 ) with respect to a model structure. These models have been refined by a version of the Hendrickson-Konnert procedure modified to incorporate the phase information derived from molecular replacement (13) . Atomic coordinates derived from the interpretation of these electron density maps are being deposited with the Brookhaven Protein Data Bank simultaneously with publication ofthis paper (acquisition nos. 1RS1, 1RR1, 1RM2, 1RS3, 1R04, 1RS5, 1R06, 1R07). pocket can be entered by way of a pore on the floor of the canyon (Fig. 2 ). The compounds with a seven-membered aliphatic chain and an aliphatic group (methyl or ethyl) on the oxazoline group that have been examined thus far bind in one orientation, while the other compounds examined here bind in the opposite direction ( Fig. 1) . Indicators of orientation are the relative size of the denser aromatic groups at either end and a constriction in the bigger density showing separation of the oxazoline-phenyl group and the site of the denser chlorine atoms in compound II and compound VII (Fig. 3) . Previously it had been assumed that compound I(S) and compound IV were oriented in an identical way (8) . The improved analytical procedures (described above) show that the predominant orientation of compound IV is in the opposite direction to that of compound I(S), with the positions of the isoxazole group and oxazoline-phenyl group exchanged. However, the clarity of the density for compound IV is not as good as that of any of the other compounds nor as that of the viral protein. Hence, it would seem possible that compound IV can bind in both directions, with a preference in the opposite sense to that of compound I(S). In the earlier analysis, it had been concluded that compound I(S) and compound IV had the same orientation because of the visibility of the additional methyl on compound I(S) in a difference map between these two compounds. Although this methyl gave rise to by far the largest positive feature in the difference map, there were other smaller positive as well as negative features in the vicinity of the WIN-binding pocket. The additional methyl of compound I(S) does not superimpose on any atom of the differently oriented compound IV, giving rise to the major feature in the difference map.
The interactions between the WIN compounds and the virus are almost entirely hydrophobic (Fig. 4) . These compounds displace two water molecules from the WIN pocket, and the conformational changes induced primarily on the "FMDV loop" alter the binding sites of a further four water molecules. The electron density of all of the compounds is significantly lower in the aliphatic chain, suggesting that it might have a small degree of disorder. The occupancy of the compounds is roughly 60% in the crystal (Table 1) , probably depending on the length of time of the crystal soak, the type of compound, and its solubility. There is no apparent preference of substitution at any of the 20 crystallographically independent sites in the virus.
The environments of compound II and compound VII (Fig.  4) represent the two major alternative and opposite binding modes, depending on the particular compound. The phenyl ring of compound VII (Fig. 4B) (Fig. 4A) and Asn-1219 has also been found. The shift in the position of the isoxazole ring in compound IV compared to compound VII (Fig. 4B ) leads to two possible hydrogen bonds with the side chain of Asn-1219. Of special interest is compound V with its additional methyl group on the oxazoline ring. Thus, it is like compound I but has an n = 5 instead of an n = 7 aliphatic chain. This compound binds at the closed end of the pocket and resembles the binding mode of compound VI. However, the additional methyl influences the location of the compound in the pocket, translating the whole structure by about 0.8 A towards the "pore." The appearance of the electron density map and likely steric hindrances seen in the model is consistent with the S isomer used for soaking the crystals. In contrast, racemic mixtures were used for soaking the crystal with compounds I, II, and III. Compounds I and III showed preference for binding only the S enantiomer, consistent with MIC values about 1/10th that for their R enantiomer. The less active compound I(R) also has been studied independently and found to bind in a manner similar to compound I(S), except for the methyl group on the asymmetric carbon. §In this manuscript, residues are labeled with a four digit notation. The first digit represents the viral protein (1, 2, 3, and 4 When the WIN compounds are bound, three stretches of the VP1 polypeptide chain occupy conformations distinctly different from the native HRV14 structure. The residues between 1213 and 1224 ( Fig. SA) (part of the chain leading from the "FMDV loop" to (H) are pushed out of the drug-binding site by distances of up to 4.5 A in C" positions (Fig. 6) . A smaller but still considerable displacement (Fig.  5B ) of residues 1151-1159 is also evident. Even smaller changes are found for the region between residues 1100 and 1110. The conformational changes were found to be largely independent (less than 0.2 A for any main-chain atom) of the particular compound bound to the virus. The three displaced chain segments are associated with the (3-sheet forming one side of the VP1 (-barrel. Hence, the conformational changes induced by drug binding are a concerted effect, causing the systematic movement of a (3-sheet (Fig. 6) . There appear to be two distinct energy minima corresponding to the native and drug-bound conformations.
Drug-Resistant Mutants
Two classes of drug-resistant mutants have been identified: a high-resistance class that replicated efficiently in high concentrations of drug (18 pug/ml), and a low-resistance class that could replicate only in low (0.3 ,ug/ml) concentrations of drug. The frequencies of the high-resistance mutants (1 per 104 plaque-forming units) were consistent with expectations for single-step mutations. The latter rate corresponds to the frequency of mutations seen in the search for escape mutants to neutralizing antibodies (14) . Indeed, they may be considered as escape mutants to the drug. Thus, it was anticipated that these mutants would have single amino acid substitutions.
High-resistance mutants were selected in the presence of compound IV and compound I. The sites of mutations were determined by sequencing the RNA in the region encoding amino acids that line the WIN-binding site. All mutants so far characterized have base substitutions in codons specifying amino acids 1188 (valine -* leucine or methionine) or 1199 (cysteine -+ tryptophan, arginine, or tyrosine). Clone SW12, selected with compound IV (Table 2) , has substituted leucine for Val-1188. This mutant propagated well and crystallized easily. A difference electron density map (Fig. 7) confirmed the identity of the mutated amino acid and also showed that there were no other visible mutations or conformational differences. Fig. 8A shows the steric crowding of the phenyl group of compound IV (modeled as bound to wild-type virus) with the mutant leucine residue at position 1188 where the nearest approach is 1.9 A. High MIC values (low activity) with compound IV were observed for mutant SW12, HRV2, HRV39, and HRV49, all of which have a leucine at the homologous position to 1188 in HRV14 (Table 2) . However, compound I(S) is more active with respect to the mutated HRV14 virus. Therefore, it is of interest that the aliphatic chain of compound I would have relatively little steric hindrance (nearest approach is 2.9 A) with a leucine at position 1188 (Fig. 8B) because of the opposite orientation of compound I to compound IV. Similarly, compound I has a much greater activity than compound IV in HRV2, HRV39, and HRV49, demonstrating that the opposite orientation of compounds IV and I observed crystallographically is roughly consistent with their observed antiviral activity. These observations break down for the shorter n = 5 chain compounds, which have relatively high activity in HRV2. This might be the result of other compensating changes in HRV2 and the possibility that these compounds do not fully penetrate to the end of the WIN pocket. Similarly the greater loss of activity of compound I(S) compared to IV on mutating residue 1188 from valine to leucine cannot be explained readily. The most commonly isolated mutation was cysteine to tryptophan at position 1199. The large tryptophan residue presumably sterically hinders the binding of compound I and compound IV (with respect to which the mutants were selected). Both of these compounds possess an n = 7-member-long aliphatic chain. However, compounds V and VI, with their shorter aliphatic chains of n = 5, bind at the closed end of the pocket in the wild type and presumably would not be expected to be hindered by the occurrence of the tryptophan residue (Fig. 8C) . This is consistent with the observed retention of antiviral activity by these compounds against this mutant. it is unclear why compound I binds in the opposite direction to compound IV. The differences of antiviral activity appear to be a product of binding affinity, the mode of binding, and the delivery ofthe compound to the virus. In a previous paper (8) , two possible mechanisms for the activity of the WIN compounds were suggested: (i) binding of the compounds might inhibit the flow ofions through the WIN pocket into the virus interior, which would cause swelling and disassembly; and (it) binding of the compounds would stiffen VP1 and, therefore, inhibit the necessary flexibility for uncoating. Although the diffusion of heavy metal ions into the virus interior does occur (1), systematic analysis of the refined HRV14 structure does not reveal any special channels. Furthermore, the interior of the pocket, where the n = 5 compounds bind, would not be an optimal site for stopping ion flow. Thus, the ion-flow hypothesis now seems less probable. On the other hand, hypothesis ii has some confirmation in the light of the observation that the SW12 mutant (Val-1188 -+ Leu) is significantly more resistant to thermal inactivation in the presence of drugs than is wild-type virus (F.J.D., unpublished results). Thus, filling the pocket with WIN compounds or WIN compounds and larger amino acid side chains can improve stability and decrease uncoating potential.
